Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
1.730
+0.030 (1.76%)
At close: Nov 13, 2026, 4:00 PM EST
1.760
+0.030 (1.73%)
After-hours: Nov 13, 2026, 7:30 PM EST
Voyager Therapeutics Stock Forecast
VYGR's stock price has decreased by -59.29% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 11 analysts polled by S&P Global, Voyager Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $14.22. The average 1-year stock price forecast is 721.97% higher than the current stock price, while the lowest is $8.00 (+362.43%) and the highest is $25 (+1,345.09%).
Price Target: $14.22 (+721.97%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Voyager Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +1,345.09% | Nov 13, 2026 |
| Wedbush | Wedbush | Buy Maintains $8 | Buy | Maintains | $8 | +362.43% | Nov 10, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $18 → $12 | Buy | Maintains | $18 → $12 | +593.64% | Nov 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $12 | Buy | Maintains | $12 | +593.64% | Nov 6, 2026 |
Unknown Analyst Wells Fargo No rating | Wells Fargo | Buy Maintains $10 | Buy | Maintains | $10 | +478.03% | Oct 2, 2026 |
Financial Forecast
Revenue This Year
15.37M
from 40.37M
Decreased by -61.92%
Revenue Next Year
44.74M
from 15.37M
Increased by 191.00%
EPS This Year
-1.65
from -2.04
EPS Next Year
-1.28
from -1.65
EPS and Forward PE are based on non-GAAP adjusted numbers.